Clinical trial NCT03723486: Bariatric Surgery: Microbiome & Diabetes
Official title: Changes in the Intestinal and Oral Microbiome of Morbidly Obese Patients Undergoing Gastric Bypass Surgery in Relation to Insulin Resistance and Metabolic Syndrome
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Obesity
Keywords: Morbidly obese
Insulin resistance
Metabolic syndrome
Intestinal microbiome
Gastric bypass
Oral microbiome
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
Collaborators: name: Canadian Institutes of Health Research (CIHR)
First posted: 2018-10-29
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Obese patients undergoing RYGB surgery.

Brief summary: This study is a prospective cohort study, following 80 morbidly obese patients undergoing bariatric surgery, specifically Roux-en-Y gastric bypass (RYGB). The investigators are measuring intestinal microbiota (IM) and oral microbiota (OM) at the beginning before any treatment, at the time of surgery, which is after a very low calorie standard diet, and 1 and 6 months after surgery. The investigators assess whether changes in IM are related to changes in insulin resistance (IR), other features of the metabolic syndrome (MetS) and OM.

Detailed description: Morbid obesity is associated with not only type 2 diabetes (T2D) of morbidly obese patients), but also cardiovascular complications, all of which remarkably improved and even resolved with bariatric surgery, of which the RYGB surgery has become the gold standard. Many studies have shown that within a few weeks post-RYGB there is dramatic improvement in IR and/or T2D independent of weight loss that ensues. These results led us to hypothesize that changes in intestinal microbiome (IM) composition and metagenome may be independently associated with improvement in metabolic parameters in humans undergoing RYGB.

Another aspect of RYGB that has not been studied is the potential changes in oral microbiome (OM) and salivary proteome (SP) and their relationship with weight loss and metabolic improvement. Understanding the OM and SP in morbidly obese patients before and after RYGB is important because shifts in the OM and SP may explain the susceptibility of these patients for oral infections like periodontal disease, which is more prevalent and severe in this population, particularly if T2D is present To our knowledge there are no longitudinal studies the relation between oral and intestinal microbiome before and after bariatric surgery. Furthermore, there are no studies looking at the effect of weight-reduction with the very low calorie diet (VLCD) Optifast regimen on IM, which the investigators plan to do. As IM may contribute to obesity and IR/T2D, the latter being the most dominant feature of the MetS. However, whether specific IM compositions are associated with improvement of obesity, IR/T2D and other features of the MetS is not clear; and the effects of RYGB on IM for treatment of these disorders in morbid obesity have not been well studied.

The investigators will conduct a prospective observational study of morbidly obese patients undergoing RYGB, in which the investigators will measure the intestinal microbiome before and after surgery along with insulin resistance and metabolic syndrome. Baseline measurements will be done before the pre-operative run-in with the very low calorie Optifast regimen (800 kcal/d) given before the laparoscopic RYGB (1 week/100 lbs body weight) to reduce the liver size for surgical access. Preoperatively, Optifast likely leads to changes in IM (never assessed) in addition to weight loss and improvement in MetS parameters. Aim: To track the changes in IM structure and function (metagenome) of morbidly obese patients undergoing laparoscopic RYGB through 3 stages - a) before vs. after pre-op Optifast weight reduction treatment 24; and post-op RYGB at b) 1 month; and at c) 6 months. The investigators will correlate the specific changes in IM through these stages, to improvement in IR and other features of the MetS. At the same time points the investigators will also measure the OM, salivary flow rate and SP, as well as oral inflammatory load.

Eligibility criteria: Inclusion Criteria:

* Morbidly obese patients (BMI \> 40 kg/m2 or BMI \>35-40 kg/m2 with other severe weight loss responsive comorbidities, undergoing laparoscopic RYGB surgery).

Exclusion Criteria:

* regular intake of non-steroidal anti-inflammatory drugs; prebiotics, probiotics or antibiotics or any experimental drug in the 3 months prior to study entry; type 1 diabetes, chronic gastrointestinal diseases, previous gastrointestinal surgery modifying the anatomy, smoking; pregnancy or breastfeeding; patients not tolerating Optifast; bariatric surgery other than RYGB patients.

Primary outcomes:
measure: Change in HOMA-IR
timeFrame: Change from Baseline HOMA-IR at 6 months post bariatric surgery
Secondary outcomes:
measure: Stool Sample: 16S sequencing
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Stool Sample: qPCR
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Stool Sample: Short Chain fatty acid
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Stool Sample: Metagenome.
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Appetite assessment
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Anthropometry:Height
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Anthropometry: weight
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Anthropometry: Waist circumference
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Anthropometry: Hip-circumference
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Questionnaires: Food record
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Questionnaires: Activity Log
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Questionnaires: Environmental questionnaire
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Questionnaires: Dental questionnaire,
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Oral microbiome: Saliva
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Oral microbiome: Mouth rinse
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Oral microbiome: Oral Plaque
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Oral microbiome: Tongue plaque
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: C peptide
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: HbA1c
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Glucose
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Fasting Insulin
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Plasma endotoxin
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
measure: Gut Hormone
timeFrame: 4 time points; pre-Optifast (baseline), post-Optifast (at the time of surgery), 1 and 6 months post surgery
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: University Health Network, Toronto General Hospital
state: Ontario
Study officials:
affiliation: University Health Network, Toronto
name: Johane P Allard, MD, FRCPC
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lewis MC, Phillips ML, Slavotinek JP, Kow L, Thompson CH, Toouli J. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg. 2006 Jun;16(6):697-701. doi: 10.1381/096089206777346682.
citation: Chaffee BW, Weston SJ. Association between chronic periodontal disease and obesity: a systematic review and meta-analysis. J Periodontol. 2010 Dec;81(12):1708-24. doi: 10.1902/jop.2010.100321. Epub 2010 Aug 19.
citation: Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2014 Feb;2(2):152-64. doi: 10.1016/S2213-8587(13)70218-3. Epub 2014 Feb 3.
citation: Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T, Bornstein SR. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J. 2013 Dec;13(6):514-22. doi: 10.1038/tpj.2012.43. Epub 2012 Oct 2.
citation: Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012 Oct 4;490(7418):55-60. doi: 10.1038/nature11450. Epub 2012 Sep 26.
citation: Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jorgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clement K, Dore J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T; MetaHIT consortium; Bork P, Wang J, Ehrlich SD, Pedersen O. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013 Aug 29;500(7464):541-6. doi: 10.1038/nature12506.
citation: Arimatsu K, Yamada H, Miyazawa H, Minagawa T, Nakajima M, Ryder MI, Gotoh K, Motooka D, Nakamura S, Iida T, Yamazaki K. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep. 2014 May 6;4:4828. doi: 10.1038/srep04828.